牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$灿菲特生物制药(CANF)$ AW - Amendment Withdrawal Request Filed: 2019-07-12 AccNo: 0001213900-19-012598 Size: 8 KB 网页链接
$灿菲特生物制药(CANF)$ F-1/A [Amend] - Registration statement for certain foreign private issuers Filed: 2019-07-12 AccNo: 0001213900-19-012600 Size: 590 KB 网页链接
$灿菲特生物制药(CANF)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2019-07-10 AccNo: 0001178913-19-001863 Size: 114 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-07-09 AccNo: 0001213900-19-012323 Size: 11 KB 网页链接
$灿菲特生物制药(CANF)$ F-1/A [Amend] - Registration statement for certain foreign private issuers Filed: 2019-06-28 AccNo: 0001213900-19-011778 Size: 589 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-06-18 AccNo: 0001213900-19-010971 Size: 11 KB 网页链接
$灿菲特生物制药(CANF)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2019-06-14 AccNo: 0001178913-19-001708 Size: 38 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-06-12 AccNo: 0001213900-19-010613 Size: 11 KB 网页链接
$灿菲特生物制药(CANF)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2019-06-06 AccNo: 0001178913-19-001682 Size: 58 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-06-03 AccNo: 0001213900-19-009919 Size: 139 KB 网页链接